Huang Hong-yan, Jiang Ze-fei, Wang Tao, Zhang Shao-hua, Bian Li, Cao Yang, Wu Shi-kai, Song San-tai
Department of Breast Cancer, Academy of Military Medical Sciences, Beijing, China.
Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):850-3.
To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer.
Three hundred and seventy-six patients with advanced breast cancer were treated with capecitabine-based chemotherapy regimens in our department from Sep 2002 to Sep 2009. They were divided into 3 groups. The group 1 was treated with capecitabine 1000 mg/m(2) orally twice daily on d1-d14, repeated every 3 weeks. The group 2 was treated with capecitabine as group 1, and combined with docetaxel 60 - 75 mg/m(2) intravenous infusion on d1, repeated every 3 weeks. The group 3 was treated with capecitabine as group 1, and combined with vinorelbine 25 mg/m(2) intravenous infusion on d1 and d8, repeated every 3 weeks. The median treatment period of treatment was 3 cycles.
Among the 376 patients, 218 patients were evaluable for response. In the group 1 the objective response rate (ORR) was 12.8% and the clinical benefit rate (CBR) was 21.6%. The CBR but not ORR of first line therapy with capecitabine was 35.2%, significantly higher than that of more than first line therapy (17.1%, P < 0.01). The ORRs for group 2 and group 3 were 53.8% and 36.4%, respectively. In the group 2 there was no significant difference in the ORR between the first line therapy and more than first line therapy. In the group 3 the ORR of first line therapy of NX regimen was 36.4%, significantly higher than that of more than first line therapy (16.7%, P < 0.01).
The capecitabine-based chemotherapy is effective and tolerable, and can be used not only in first line but also more than first line therapy. The single agent maintenance chemotherapy after response to combined chemotherapy can prolonge the duration of treatment for patients with metastatic breast cancer.
回顾性评估以卡培他滨为基础的化疗方案治疗晚期乳腺癌的疗效和毒性。
2002年9月至2009年9月，我科376例晚期乳腺癌患者接受了以卡培他滨为基础的化疗方案。患者被分为3组。第1组患者在第1 - 14天口服卡培他滨1000mg/m²，每日2次，每3周重复。第2组患者的卡培他滨用法同第1组，并在第1天静脉输注多西他赛60 - 75mg/m²，每3周重复。第3组患者的卡培他滨用法同第1组，并在第1天和第8天静脉输注长春瑞滨25mg/m²，每3周重复。中位治疗周期为3个周期。
376例患者中，218例可评估疗效。第1组的客观缓解率（ORR）为12.8%，临床获益率（CBR）为21.6%。卡培他滨一线治疗的CBR而非ORR为35.2%，显著高于一线以上治疗（17.1%，P < 0.01）。第2组和第3组的ORR分别为53.8%和36.4%。第2组一线治疗和一线以上治疗的ORR无显著差异。第3组NX方案一线治疗的ORR为36.4%，显著高于一线以上治疗（16.7%，P < 0.01）。
以卡培他滨为基础的化疗有效且耐受性良好，可用于一线及一线以上治疗。联合化疗有效后的单药维持化疗可延长转移性乳腺癌患者的治疗时间。
